32.65
前日終値:
$32.61
開ける:
$32.42
24時間の取引高:
202.39K
Relative Volume:
0.53
時価総額:
$1.65B
収益:
$357.71M
当期純損益:
$-20.10M
株価収益率:
-82.47
EPS:
-0.3959
ネットキャッシュフロー:
$28.67M
1週間 パフォーマンス:
+0.49%
1か月 パフォーマンス:
-7.17%
6か月 パフォーマンス:
+10.38%
1年 パフォーマンス:
-9.68%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
名前
Immunocore Holdings Plc Adr
セクター
電話
01235 5430281
住所
90 PARK DRIVE, OXFORDSHIRE
IMCR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
IMCR
Immunocore Holdings Plc Adr
|
32.65 | 1.64B | 357.71M | -20.10M | 28.67M | -0.3959 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-08-25 | 再開されました | Jefferies | Buy |
2025-05-27 | 開始されました | Deutsche Bank | Buy |
2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2024-11-11 | ダウングレード | Mizuho | Outperform → Neutral |
2024-10-24 | 開始されました | UBS | Sell |
2024-10-07 | ダウングレード | Guggenheim | Buy → Neutral |
2024-04-29 | 開始されました | Leerink Partners | Outperform |
2023-11-20 | 再開されました | JP Morgan | Overweight |
2023-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
2023-10-31 | 開始されました | Robert W. Baird | Outperform |
2023-09-13 | アップグレード | JP Morgan | Neutral → Overweight |
2023-09-13 | 開始されました | Needham | Buy |
2023-08-16 | 開始されました | CapitalOne | Overweight |
2023-07-17 | 開始されました | Canaccord Genuity | Hold |
2023-03-31 | 開始されました | Mizuho | Buy |
2023-03-30 | 開始されました | Guggenheim | Buy |
2023-03-24 | 開始されました | Bryan Garnier | Buy |
2022-12-16 | アップグレード | Goldman | Neutral → Buy |
2022-11-30 | 開始されました | Barclays | Overweight |
2022-09-09 | 開始されました | Morgan Stanley | Overweight |
2022-09-08 | 開始されました | Ladenburg Thalmann | Buy |
2022-08-08 | 開始されました | Cowen | Outperform |
2022-08-02 | 開始されました | BTIG Research | Buy |
2022-02-08 | 開始されました | H.C. Wainwright | Buy |
2021-10-20 | 開始されました | Oppenheimer | Outperform |
2021-03-02 | 開始されました | Goldman | Neutral |
2021-03-02 | 開始されました | JP Morgan | Overweight |
2021-03-02 | 開始されました | Jefferies | Buy |
すべてを表示
Immunocore Holdings Plc Adr (IMCR) 最新ニュース
Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Earnings call transcript: Immunocore Q2 2025 beats revenue forecast - Investing.com
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.00 Consensus Price Target from Brokerages - Defense World
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Immunocore (IMCR) Q2 Revenue Jumps 30% - The Motley Fool
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Immunocore stock price target raised to $36 from $33 at Mizuho - Investing.com
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Immunocore Holdings ADR Earns IBD Rating Upgrade - Investor's Business Daily
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment - Yahoo Finance
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Yahoo Finance
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study - Yahoo Finance
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer - Yahoo Finance
FDA Extends INCY's Application for Opzelura Label Expansion - Yahoo Finance
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Yahoo Finance
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Brokers Set Expectations for Immunocore FY2026 Earnings - Defense World
GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR) - Defense World
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - Yahoo Finance
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings Plc Adr (IMCR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):